Results 131 to 140 of about 8,529 (239)

Workflow used for the building and validation of the pediatric brain PBPK model.

, 2019
Workflow used for the building and validation of the pediatric brain PBPK model.
Saskia N. de Wildt (6836657), Jan B. Koenderink (1798546), Frans G. M. Russel (225673), Laurens F. M. Verscheijden (6836654)   +3 more
core   +1 more source

A physiologically based pharmacokinetic/pharmacodynamic model to determine dosage regimens and withdrawal intervals of aditoprim against Streptococcus suis

Frontiers in Pharmacology
Introduction: Streptococcus suis (S. suis) is a zoonotic pathogen threatening public health. Aditoprim (ADP), a novel veterinary medicine, exhibits an antibacterial effect against S. suis.
Kun Mi, Kun Mi, Lei Sun, Lei Sun, Lan Zhang, Lan Zhang, Aoran Tang, Aoran Tang, Xiaoyuan Tian, Xiaoyuan Tian, Yixuan Hou, Yixuan Hou, Lingling Sun, Lingli Huang, Lingli Huang, Lingli Huang   +15 more
doaj   +1 more source

Analysis of biomarker utility using a PBPK/PD model for carbaryl

, 2014
There are many types of biomarkers; the two common ones are biomarkers of exposure and biomarkers of effect. The utility of a biomarker for estimating exposures or predicting risks depends on the strength of the correlation between biomarker ...
Martin Blake Phillips, Bruce eYoung, Miyoung eYoon, Yu-Mei eTan, Yu-Mei Tan, Martin B. Phillips, Miyoung Yoon, Bruce Young   +7 more
core   +1 more source

A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis. [PDF]

Front Pharmacol, 2023
Reali F, Fochesato A, Kaddi C, Visintainer R, Watson S, Levi M, Dartois V, Azer K, Marchetti L.   +8 more
europepmc   +1 more source

Population pharmacokinetic modelling of amoxicillin in human breast milk—A contribution from the ConcePTION project

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1833-1844, June 2026.
Aims Amoxicillin, a widely used β‐lactam antibiotic, requires improved pharmacokinetic characterization during breastfeeding. This study used a population pharmacokinetic (PopPK) approach to model amoxicillin concentrations in breast milk, identify variability sources and estimate infant exposure, applying worst‐case scenarios.
Sarah Baklouti, Virginie Rigourd, Alice Panchaud, Hedvig Nordeng, Karel Allegaert, Pieter Annaert, Miao‐Chan Huang, Anaelle Monfort, Monia Guidi, Peggy Gandia   +9 more
wiley   +1 more source

Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1845-1856, June 2026.
Abstract Aims The study aims to develop a physiologically‐based pharmacokinetic (PBPK) model to quantitatively evaluate the role of ATP‐binding cassette sub‐family B member 1 (ABCB1) and ATP‐binding cassette super‐family G member 2 (ABCG2) in the drug–drug interaction (DDI) between rifampin and linezolid and to predict the impact of high‐dose rifampin ...
Hoang Dat Nguyen, Vinh Hoa Pham, Richard M. Hoglund, Joel Tarning, Junjie Ding   +4 more
wiley   +1 more source

Nonclinical Considerations for Support of Pregnancy and Lactation in Clinical Trials

Birth Defects Research, Volume 118, Issue 6, June 2026.
ABSTRACT Background Pregnant and breastfeeding individuals remain underrepresented in clinical drug development, leaving health care providers and patients with limited data to inform treatment decisions. Current practice relies heavily on nonclinical developmental and reproductive toxicity (DART) studies in animals, while clinical trials typically ...
Dinesh Stanislaus, Christopher J. Bowman, Kimberly C. Brannen, Sarah N. Campion, Laura M. Carlson, Stephan Chalon, Anthony M. DeLise, Claudia Demarta‐Gatsi, Brian P. Enright, Wendy Halpern, Shermaine Mitchell‐Ryan, Vicki Sutherland, Karen Thacker, Kary Thompson, Belen Tornesi, Steven Van Cruchten, Ronald L. Wange, Tacey White, Connie L. Chen   +18 more
wiley   +1 more source

Development and validation of PBPK models for genistein and daidzein for use in a next-generation risk assessment

Frontiers in Pharmacology
IntroductionAll cosmetic ingredients must be evaluated for their safety to consumers. In the absence of in vivo data, systemic concentrations of ingredients can be predicted using Physiologically based Pharmacokinetic (PBPK) models.
A. Najjar, D. Lange, C. Géniès, J. Kuehnl, A. Zifle, C. Jacques, E. Fabian, N. Hewitt, A. Schepky   +8 more
doaj   +1 more source

The First Physiologically Based Pharmacokinetic (PBPK) Model for an Oral Vaccine Using Alpha-Tocopherol as an Adjuvant. [PDF]

Pharmaceutics, 2023
Saldanha L, Vale N.
europepmc   +1 more source

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects

, 2018
This study aimed to construct a physiologically based pharmacokinetic (PBPK) model of rifampicin that can accurately and quantitatively predict complex drug-drug interactions (DDIs) involving its saturable hepatic uptake and auto-induction.
Yuichi Sugiyama, Tobe, Yoshifusa, Yoshifusa Tobe, Haruo Imawaka, Wooin Lee, Ken-ichi Nunoya, Kenta Hashizume, Lee, Woo In, Sugiyama, Yuichi, Kota Toshimoto, Asaumi, Ryuta, Hashizume, Kenta, 이우인, Imawaka, Haruo, Toshimoto, Kota, Ryuta Asaumi   +15 more
core   +1 more source